Imaging Accurately Stages Nodal Squamous Cell Carcinoma Except in Immunosuppression

Cutaneous squamous cell carcinoma remains the second most prevalent skin malignancy, and while localized excision is often curative, a high-risk subset of patients faces a substantial threat of morbidity and mortality [1, 2]. Identifying nodal metastases at the earliest possible stage is critical, as regional involvement necessitates a shift toward aggressive interventions such as lymph node dissection or adjuvant radiotherapy (radiation treatment administered after primary surgery to reduce the risk of local or regional recurrence) [3, 4]. Current staging systems, including the American Joint Committee on Cancer and Brigham and Women’s Hospital frameworks, provide a structure for risk stratification but do not definitively establish the optimal imaging modality for baseline evaluation [5, 6]. This diagnostic uncertainty is particularly acute in immunosuppressed patients, who are known to develop more aggressive tumors with higher rates of recurrence [3, 7]. A new study now provides evidence-based insights into the comparative performance of various imaging modalities for nodal staging in these high-risk populations.